OncoMatch/Clinical Trials/NCT05472558
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Is NCT05472558 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies anti-CD19 CAR-NK for b-cell non hodgkin lymphoma.
Treatment: anti-CD19 CAR-NK — To study the safety and effectiveness of cord blood-derived CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
The puncture section of the tumor tissue was positive for CD19 expression
Allowed: CD20 negative
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Must have received: anthracycline
Previous treatment must include...anthracyclines
Cannot have received: CD19-targeted therapy
Have received any other drugs that target CD19
Lab requirements
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Glomerular filtration rate >50Ml/min
Liver function
Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL
Cardiac function
Cardiac ejection fraction (EF) ≥50%
Sufficient organ function reserve: Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL; Glomerular filtration rate >50Ml/min Cardiac ejection fraction (EF) ≥50%; Under natural indoor air environment, basic oxygen saturation >92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify